ORIGINAL ARTICLE
A Comparative Single Dose Bioequivalence Study of Extended Release Antihypertensive Drug Formulation among Healthy Human Volunteers
 
More details
Hide details
1
Vidyabharati College of Pharmacy, Amravati, India
 
 
Publication date: 2013-04-09
 
 
Corresponding author
Vivek Vijayrao Paithankar   

Vidyabharati college of pharmacy,Amravati, India
 
 
Eur J Gen Med 2013;10(2):83-89
 
KEYWORDS
ABSTRACT
The objective of this study was to compare the in vivo characteristics of diltiazem extended release formulations for once daily, which were expected to be bioequivalent. Either two capsules of a test formulation or a 1 of the reference formulation, both containing 360 mg diltiazem were administered to healthy male volunteers after keeping fast of ten hour in a randomized, open label,three period crossover design. Plasma samples obtained over the subsequent period of 72 hours were analyzed using a validated LC-MS/MS method. Safety profile and tolerability of the study medications were assessed by analysis of adverse events obtained by vital sign measurements, electrocardiography, and clinical. The 90% CI for the log transformed data for Cmax, AUC0-t,AUC0-∞ for both the test product fell in the prescribed limits of bioequivalence for narrow therapeutics index drugs i.e. 80 to 120%. This single dose study found that the test and reference products met the regulatory criteria for bioequivalence in healthy, male volunteers under fasting.
eISSN:2516-3507
Journals System - logo
Scroll to top